A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia
- 1 September 1997
- journal article
- clinical trial
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 41 (9), 1965-1972
- https://doi.org/10.1128/aac.41.9.1965
Abstract
Five hundred ninety patients were enrolled in a prospective, multicenter, randomized trial comparing the efficacy and safety of 7 to 14 days of levofloxacin treatment with that of ceftriaxone and/or cefuroxime axetil in the management of community-acquired pneumonia in adults. Patients received either intravenous and/or oral levofloxacin (500 mg once daily) or the comparative agents, parenteral ceftriaxone (1 to 2 g once to twice daily) and/or oral cefuroxime axetil (500 mg twice daily). Erythromycin or doxycycline could be added to the comparator arm at the investigator's discretion. The decision to use an intravenous or oral antimicrobial agent for initial therapy was made by the investigator. Clinical and microbiological evaluations were completed at the baseline, during treatment, 5 to 7 days posttherapy, and 3 to 4 weeks posttherapy. Four hundred fifty-six patients (226 given levofloxacin and 230 administered ceftriaxone and/or cefuroxime axetil) were evaluable for clinical efficacy. Streptococcus pneumoniae and Haemophilus influenzae were isolated in 15 and 12%, respectively, of clinically evaluable patients. One hundred fifty atypical pathogens were identified: 101 were Chlamydia pneumoniae, 41 were Mycoplasma pneumoniae, and 8 were Legionella pneumophila. Clinical success at 5 to 7 days posttherapy was superior for the levofloxacin group (96%) compared with the ceftriaxone and/or cefuroxime axetil group (90%) (95% confidence interval [CI] of -10.7 to -1.3). Among patients with typical respiratory pathogens who were evaluable for microbiological efficacy, the overall bacteriologic eradication rates were superior for levofloxacin (98%) compared with the ceftriaxone and/or cefuroxime axetil group (85%) (95% CI of -21.6 to -4.8). Levofloxacin eradicated 100% of the most frequently reported respiratory pathogens (i.e., H. influenzae and S. pneumoniae) and provided a >98% clinical success rate in patients with atypical pathogens. Both levofloxacin and ceftriaxone-cefuroxime axetil eradicated 100% of the S. pneumoniae cells detected in blood culture. Drug-related adverse events were reported in 5.8% of patients receiving levofloxacin and in 8.5% of patients administered ceftriaxone and/or cefuroxime axetil. Gastrointestinal and central and peripheral nervous system adverse events were the most common events reported in each treatment group. In conclusion, these results demonstrate that treatment with levofloxacin is superior to ceftriaxone and/or cefuroxime axetil therapy in the management of community-acquired pneumonia in adults.Keywords
This publication has 24 references indexed in Scilit:
- Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia.Thorax, 1996
- Community-Acquired PneumoniaNew England Journal of Medicine, 1995
- Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibioticsAmerican Journal Of Medicine, 1991
- Infectious Complications with Respiratory Pathogens despite Ciprofloxacin TherapyNew England Journal of Medicine, 1991
- New and Emerging Etiologies for Community-Acquired Pneumonia with Implications for TherapyMedicine, 1990
- In vitro Antibacterial Activity of DR-3355, the S-(––)-Isomer of OfloxacinChemotherapy, 1990
- Randomised comparison of ceftriaxone and cefamandole therapy in lower respiratory tract infections in an elderly populationJournal of Antimicrobial Chemotherapy, 1986
- Treatment of Lower Respiratory Tract Infections with Ceftriaxone and CefotaximeRespiration, 1986
- A comparison of oral cefuroxime axetil and oral amoxycillin in lower respiratory tract infectionsJournal of Antimicrobial Chemotherapy, 1985
- Ceftriaxone A Review of its Antibacterial Activity, Pharmacological Properties and Therapeutic UseDrugs, 1984